Aging, Telomere Shortening, Vascular Diseases
Conditions
Brief summary
The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.
Detailed description
The purpose of this clinical trial is to examine whether activation of autophagy with TA-65 which activates telomerase, improves microvascular function and blood pressure in an older population
Interventions
DIETARY_SUPPLEMENTTA-65
TA-65 is a purified small molecule extracted from Astragalus root
OTHERPlacebo
Inactive formulation
Sponsors
Medical College of Wisconsin
University of Louisville
Penn State University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy Adults 18 - 35 and 65+ years of age * Subjects with clinical diagnosis of CAD
Exclusion criteria
will include: * 36-64 years of age without clinical diagnosis of CAD * Self-reported habitual vigorous exercise (\>20 min, 3 times per week, 1 yr) * Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke) * Heart Failure * Renal Impairment * \>3 Pre-existing Cardiovascular Risk Factors (healthy groups only) * Type 1 or type 2 diabetes * Uncontrolled hypertension * Current tobacco use or within last 6 months * BMI \> 35 * Hyperlipidemia * Hypercholesterolemia * Use of anti-coagulant drugs * Use of anti-platelet drugs * Erectile dysfunction medication in the past 6 months * Use of topical/non-topical steroids in last 6 months * Hormone replacement therapy (Post-Menopause or Gender Reassignment) * History of retinopathy * Documented neuromuscular disorders * Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity) * Pregnancy (young female subjects) * Allergy to lidocaine * Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months * Active COVID-19 or within the past 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis | 28 days | Cutaneous microvascular function measured via laser Doppler flowmetry coupled with intradermal microdialysis of non-specific nitric oxide synthase inhibitor, L-NAME |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Systemic Blood Pressure | 28 days | Brachial systolic, and diastolic blood pressure will be measured via standard brachial blood pressure cuff |
Contacts
CONTACTAndreas Beyer, Ph.D.
CONTACTWilliam Hughes, Ph.D.
PRINCIPAL_INVESTIGATORAndreas Beyer, Ph.D.
Associate Professor
Outcome results
None listed